Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection

Del Re, 2021, A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC, Cancer Immunol. Immunother., 70, 1667, 10.1007/s00262-020-02810-6 Grenda, 2020, Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients, Front. Oncol., 10 Berghmans, 2020, Mass spectrometry imaging reveals neutrophil defensins as additional biomarkers for anti-PD-(L)1 immunotherapy response in NSCLC patients, Cancers, 12, 863, 10.3390/cancers12040863 Callejo, 2021, Interrelations between Patients’ clinicopathological characteristics and their association with response to immunotherapy in a real-world cohort of NSCLC patients, Cancers, 13, 3249, 10.3390/cancers13133249 Jin, 2019, The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in chinese patients with NSCLC, J. Thoracic Oncol., 14, 1378, 10.1016/j.jtho.2019.04.007 Blons, 2019, Molecular markers and prediction of response to immunotherapy in NSCLC, and update, J. Thoracic Dis., 10.21037/jtd.2018.12.48 Cascone, 2021, Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, Nat. Med., 27, 504, 10.1038/s41591-020-01224-2 Forde, 2018, Neoadjuvant PD-1 blockade in resectable lung cancer, New Engl. J. Med., 378, 1976, 10.1056/NEJMoa1716078 Wu, 2021, Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non–small-cell lung cancer: KEYNOTE-042 China Study, Int. J. Cancer, 148, 2313, 10.1002/ijc.33399 Langer, 2016, Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study, Lancet Oncol., 17, 1497, 10.1016/S1470-2045(16)30498-3 Wu, 2019, Nivolumab versus docetaxel in a predominantly chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial, J. Thoracic Oncol., 14, 867, 10.1016/j.jtho.2019.01.006 Carbone, 2017, First-line nivolumab in stage IV or recurrent non–small-cell lung cancer, N. Engl. J. Med., 376, 2415, 10.1056/NEJMoa1613493 Paz-Ares, 2018, Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer, N. Engl. J. Med., 379, 2040, 10.1056/NEJMoa1810865 Choi, 2021, Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study, Transl. Lung Cancer Res., 10, 2551, 10.21037/tlcr-21-206 Keegan, 2020, Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC, J. ImmunoTher. Cancer, 8, e000678, 10.1136/jitc-2020-000678 Hurkmans, 2020, Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients, Cancer Immunol. Immunother. Biol. Res. Modif., 69, 771, 10.1007/s00262-020-02506-x Skoulidis, 2018, STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS -mutant lung adenocarcinoma, Cancer Discov., 8, 822, 10.1158/2159-8290.CD-18-0099 Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314 Bai, 2020, Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort stud, J. ImmunoTher. Cancer, 8, e000381, 10.1136/jitc-2019-000381 Thompson, 2020, Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma, J. ImmunoTher. Cancer, 8, e000974, 10.1136/jitc-2020-000974 NCCN. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology™ Non-Small Cell Lung Cancer 2021. Bakos, 2018, Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity, J. ImmunoTher. Cancer, 6, 86-, 10.1186/s40425-018-0398-7 Hogan, 2011, Surgery induced immunosuppression, Surgeon (Edinburgh), 9, 38, 10.1016/j.surge.2010.07.011 Onuma, 2020, Surgical Stress Promotes Tumor Progression: A Focus on the Impact of the Immune Response, J. Clin. Med., 9, 4096, 10.3390/jcm9124096 Tang, 2020, Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies, Clin. Transl. Med., 10, 199, 10.1002/ctm2.24 Shaked, 2016, Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects, Nat. Rev. Clin. Oncol., 13, 611, 10.1038/nrclinonc.2016.57 Veenhof, 2012, Surgical stress response and postoperative immune function after laparoscopy or open surgery with fast track or standard perioperative care a randomized trial, Ann. Surg., 255, 216, 10.1097/SLA.0b013e31824336e2 Okamura, 2015, Factors affecting cytokine change after esophagectomy for esophageal cancer, Ann. Surg. Oncol., 22, 3130, 10.1245/s10434-014-4348-4 Maas, 2014, Immunological changes after minimally invasive or conventional esophageal resection for cancer: a randomized trial, World J. Surg., 38, 131, 10.1007/s00268-013-2233-0 Matzner, 2020, Harnessing cancer immunotherapy during the unexploited immediate perioperative period, Nat. Rev. Clin. Oncol., 17, 313, 10.1038/s41571-019-0319-9 Shaashua, 2017, Perioperative COX-2 and β-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial, Clin. Cancer Res., 23, 4651, 10.1158/1078-0432.CCR-17-0152 Brivio, 2006, Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C, Anticancer Res., 26, 599 Yang, 2017, Long-term survival based on the surgical approach to lobectomy for clinical stage I nonsmall cell lung cancer: comparison of robotic, video-assisted thoracic surgery, and thoracotomy lobectomy, Ann. Surg., 265, 431, 10.1097/SLA.0000000000001708 Assi, 2015, Hospital readmission after pulmonary lobectomy is not affected by surgical approach, Ann. Thoracic Surg., 99, 393, 10.1016/j.athoracsur.2014.10.014 Kneuertz, 2019, Hospital cost and clinical effectiveness of robotic-assisted versus video-assisted thoracoscopic and open lobectomy: A propensity score–weighted comparison, J. Thoracic Cardiovas. Surg., 157, 2018, 10.1016/j.jtcvs.2018.12.101 Xu, 2015, Surgical trauma induces postoperative T-cell dysfunction in lung cancer patients through the programmed death-1 pathway, Cancer Immunol. Immunother., 64, 1383, 10.1007/s00262-015-1740-2 Corsini, 2020, Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively, Lung Cancer (Amsterdam, Netherlands), 146, 303, 10.1016/j.lungcan.2020.06.022 Van Haren, 2018, Enhanced recovery decreases pulmonary and cardiac complications after thoracotomy for lung cancer, The Annals of thoracic surgery, 106, 272, 10.1016/j.athoracsur.2018.01.088 Goldstraw, 2007, The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours, J. Thoracic Oncol., 2, 706, 10.1097/JTO.0b013e31812f3c1a Benjamini, 1995, Controlling the false discovery rate: A practical and powerful approach to multiple testing, J. Royal Stat. Soc. Series B, Method., 57, 289 Cader, 2020, A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma, Nat. Med., 26, 1468, 10.1038/s41591-020-1006-1 Mazzaschi, 2020, Soluble PD-L1 and circulating CD8+PD-1+ and NK cells enclose a prognostic and predictive immune effector score in immunotherapy treated NSCLC patients, Lung Cancer (Amsterdam, Netherlands), 148, 1, 10.1016/j.lungcan.2020.07.028 Liang, 2018, Elevated peripheral blood B lymphocytes and CD3 + CD4 - CD8 - T lymphocytes in patients with non-small cell lung cancer: A preliminary study on peripheral immune profile, Oncol. Lett., 15, 8387 Vekens, 2021, The Value of 18F-FDG PET/CT in predicting the response to PD-1 blocking immunotherapy in advanced NSCLC patients with high-level PD-L1 expression, Clin. Lung Cancer, 22, 432, 10.1016/j.cllc.2021.03.001 Polverari, 2020, 18F-FDG Pet parameters and radiomics features analysis in advanced Nsclc treated with immunotherapy as predictors of therapy response and survival, Cancers, 12, 1163, 10.3390/cancers12051163 Monaco, 2021, Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (NSCLC): A real world experience, Cancers, 13, 1634, 10.3390/cancers13071634 Laza‐Briviesca, 2021, Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial, Clin. Transl. Med., 11, 10.1002/ctm2.491 Goldfarb, 2011, Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses, Ann. Surg., 253, 798, 10.1097/SLA.0b013e318211d7b5